Skip to content
    Clinical Trials

    Outcomes and Prognostic Factors in Unresected Nonrhabdomyosarcoma Soft Tissue Sarcoma

    Weiss et alCancer

    Outcomes and Prognostic Factors in Unresected Nonrhabdomyosarcoma Soft Tissue Sarcoma
    An analysis from the International Soft Tissue Sarcoma Consortium (INSTRuCT)—encompassing data from the Children’s Oncology Group (COG ARST0332), European Paediatric Soft Tissue Sarcoma Study Group (EpSSG NRSTS-2005), Cooperative Weichteilsarkom Studiengruppe (CWS-91, -96, and -2002P), and the MMT-95 study—evaluated prognostic variables and outcomes in 661 patients aged <21 years (median age 12 years; range, 0–21) with initially unresected localized nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) treated between 1988 and 2016. All patients received preoperative chemotherapy, predominantly alkylator- and/or anthracycline-based regimens, while neoadjuvant radiation therapy (RT) was protocol-specified in ARST0332 and higher-risk NRSTS-2005 cohorts, but variable in CWS and MMT-95.
    Tumor characteristics across the cohort showed a predominance of tumors >5 cm (73%), extremity localization (55%), T2 stage (55%), and N0 status (87%). Overall 5-year event-free survival (EFS) was 57.6% (95% CI, 53.5%–61.4%). Independent prognostic factors for EFS included tumor histology (synovial sarcoma was most favorable and malignant peripheral nerve sheath tumor least favorable; p < .0001), invasiveness (p = .002), and primary site (extremity most favorable; p = .02).
    Protocols incorporating specified neoadjuvant RT (ARST0332 and NRSTS-2005) achieved higher delayed complete or microscopic resection margins (R0/R1 of 98% and 96%, respectively) compared to trials with variable RT utilization (CWS, 81%; MMT-95, 46%; p < .0001). Furthermore, patients with tumors >5 cm synovial sarcoma treated on contemporary protocols (ARST0332 and NRSTS-2005) experienced more favorable EFS compared to earlier protocols.

    Key Takeaways

    • Patients enrolled in protocols with specified neoadjuvant radiation achieved higher R0/R1 delayed resection rates (98% in ARST0332 and 96% in NRSTS-2005) compared to studies with variable radiation incorporation (81% in CWS and 46% in MMT-95; p < .0001).
    • Overall 5-year event-free survival was 57.6% (95% CI, 53.5%–61.4%), with independent prognostic factors identified as histology (synovial sarcoma most favorable, malignant peripheral nerve sheath tumor least favorable; p < .0001), tumor invasiveness (p = .002), and primary site (extremity most favorable; p = .02).